Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 5;13:21454. doi: 10.1038/s41598-023-48830-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Survival analyses of ER + /HER2- breast cancer patients with lower and higher predicted risk score from CoxPH models. (a) The multivariate correlation analysis of the predicted ER activity score, diagnostic age, and stage of testing samples with PFS. Exp(coef) is the hazard ratio (HR), The upper and lower 95% were the 95% confidence interval. P corresponds to the p-value. A predicted risk score for each testing sample in the testing cohort was generated using model fitted using ER activity score, clinical data and PFS of the training cohort. ER + /HER2- patients were assigned with a higher and lower predicted risk for PFS using a quantile 0.9 as cut-off. (b) Comparison of progression free survival (PFS) of predicted higher risk ER + /HER2- patients with lower risk ER + /HER2- patients. (c) Comparison of overall survival (OS) of predicted higher risk ER + /HER2- patients with lower risk ER + /HER2- patients. (d) Comparison of PFS of predicted lower risk ER + /HER2- patients with triple negative breast cancer (TNBC) patients. (e) Comparison of OS of predicted lower risk ER + /HER2- patients with TNBC patients. (f) Comparison of PFS of predicted higher risk ER + /HER2- patients with TNBC patients. (g) Comparison of OS of predicted higher risk ER + /HER2- patients with TNBC patients.